Spectral AI (NASDAQ:MDAI) said it remains on track toward potential U.S. regulatory clearance and commercialization of its DeepView system for burn assessment, while reporting lower first-quarter research and development revenue tied to the completion of work under a federal contract.
On the company’s first-quarter 2026 earnings call, Chief Executive Officer Vincent Capone said the period was defined by “progress and preparation,” citing ongoing discussions with the U.S. Food and Drug Administration, expanded government funding and steps toward building a commercial infrastructure.
